ANI Pharmaceuticals
ANIP
116 hedge funds and large institutions have $253M invested in ANI Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 37 increasing their positions, 39 reducing their positions, and 8 closing their positions.
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
9% more funds holding
Funds holding: 106 → 116 (+10)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $263M → $253M (-$10.8M)
5% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 39
2.39% less ownership
Funds ownership: 59.05% → 56.66% (-2.4%)
70% less call options, than puts
Call options by funds: $245K | Put options by funds: $806K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$1.88M |
| 2 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
+$1.77M |
| 3 |
CIC
Cornercap Investment Counsel
Atlanta,
Georgia
|
+$1.25M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$1.09M |
| 5 |
ICOM
Investment Counselors of Maryland
Baltimore,
Maryland
|
+$1.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.61M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$1.75M |
| 3 |
Renaissance Technologies
New York
|
-$1.63M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.35M |
| 5 |
Two Sigma Investments
New York
|
-$918K |
ANIP Hedge Fund Activity: Q2 2021 in Review
116 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q2 2021, worth a combined $253M — down 4.1% from $263M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ANIP positions and 8 closed out — a net gain of 10 holders — while 37 added to existing stakes and 39 trimmed.
The largest buyer was Parkman Healthcare Partners, opening a new position worth an estimated $1.88M. The largest seller was BlackRock, cutting an estimated $3.61M.
- 116 institutional investors held ANI Pharmaceuticals (ANIP) as of Q2 2021, up from 106 in Q1 2021.
- Funds reported $253M of ANI Pharmaceuticals stock for Q2 2021, down 4.1% quarter-over-quarter.
- 18 funds opened new ANI Pharmaceuticals positions in Q2 2021 and 8 closed out, a net change of +10 holders.
- The largest ANI Pharmaceuticals buyer in Q2 2021 was Parkman Healthcare Partners, an estimated $1.88M added.
- The largest ANI Pharmaceuticals seller in Q2 2021 was BlackRock, an estimated $3.61M sold.
Based on aggregated 13F filings for Q2 2021.